Polyrizon (PLRZ) News Today $0.48 -0.02 (-3.97%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Polyrizon Advances Clinical Strategy For PL-14 Allergy Blocker Ahead Of FDA MeetingMarch 29 at 2:30 PM | nasdaq.comPolyrizon structures clinical strategy for allergy blocker PL-14March 28 at 2:50 AM | markets.businessinsider.comPolyrizon Prepares Clinical Strategy for Allergy Blocker PL-14March 27 at 5:07 PM | tipranks.comPolyrizon Ltd.: Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue TreatmentMarch 27 at 12:22 PM | finanznachrichten.dePolyrizon begins preclinical studies for seizure treatmentMarch 27 at 12:22 PM | uk.investing.comPolyrizon begins BZDs studies for treating ARS and status epilepticusMarch 27 at 12:22 PM | markets.businessinsider.comPolyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission MeetingMarch 27 at 8:25 AM | globenewswire.comPolyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue TreatmentMarch 25, 2025 | globenewswire.comClearmind Medicine To Develop Novel Intranasal Formulation With PolyrizonMarch 21, 2025 | nasdaq.comClearmind signs non-binding LOI with Polyrizon for intranasal drug deliveryMarch 19, 2025 | markets.businessinsider.comPolyrizon Expands Intranasal Platform for Psychedelic TreatmentsMarch 14, 2025 | tipranks.comPolyrizon signs non-binding LOI to expand its intranasal drug delivery platformMarch 14, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformMarch 14, 2025 | finanznachrichten.dePolyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based TreatmentsMarch 14, 2025 | globenewswire.comPolyrizon launches preclinical studies for intranasal naloxoneMarch 13, 2025 | markets.businessinsider.comPolyrizon Ltd. Schedules Annual General Meeting for April 2025March 13, 2025 | tipranks.comPolyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformMarch 13, 2025 | globenewswire.comPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024March 11, 2025 | globenewswire.comPolyrizon initiates preclinical studies for intranasal naloxoneMarch 10, 2025 | markets.businessinsider.comPolyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T PlatformMarch 10, 2025 | globenewswire.comPolyrizon files divisional patent application with Israel Patent OfficeJanuary 30, 2025 | markets.businessinsider.comPolyrizon files patent for nasal drug delivery techJanuary 30, 2025 | msn.comPolyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery PlatformJanuary 30, 2025 | globenewswire.comPolyrizon commences GMP manufacturing process for PL-14 allergy blockerJanuary 24, 2025 | markets.businessinsider.comPolyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialJanuary 23, 2025 | globenewswire.comPolyrizon announces publication of patent application for hydrogel nasal techDecember 30, 2024 | markets.businessinsider.comPolyrizon files to sell 2.42M ordinary shares for holdersDecember 30, 2024 | markets.businessinsider.comRisk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity FuturesDecember 30, 2024 | msn.comPolyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal TechnologiesDecember 30, 2024 | globenewswire.comPolyrizon appoints Michal Meir as senior director, regulatory & clinical affairsDecember 20, 2024 | markets.businessinsider.comPolyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trialDecember 19, 2024 | markets.businessinsider.comPolyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical AffairsDecember 19, 2024 | globenewswire.comPolyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy BlockerDecember 18, 2024 | globenewswire.comPolyrizon Announces Appointment of VP of Regulatory Affairs and Quality AssuranceDecember 13, 2024 | globenewswire.comPolyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialDecember 2, 2024 | globenewswire.com Remove Ads Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRZ Media Mentions By Week PLRZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRZ News Sentiment▼0.460.81▲Average Medical News Sentiment PLRZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRZ Articles This Week▼92▲PLRZ Articles Average Week Remove Ads Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aytu BioPharma News NKGen Biotech News Hoth Therapeutics News BioXcel Therapeutics News Cyclerion Therapeutics News Omega Therapeutics News Biofrontera News Onconetix News Alzamend Neuro News Avalon GloboCare News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRZ) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRZ Stock Free PLRZ Stock Alerts